News >

Alectinib Approved in China for ALK+ NSCLC

Jason M. Broderick @jasoncology
Published: Tuesday, Aug 21, 2018

Dr. Sandra Horning

Sandra Horning, MD
The China National Drug Administration (CNDA) has approved alectinib (Alecensa) for the treatment of patients with ALK-positive, advanced non–small cell lung cancer (NSCLC), according to Roche, the manufacturer of the second-generation ALK inhibitor.

China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer. Roche. Published August 20, 2018. Accessed August 21, 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication